Please login to the form below

Not currently logged in
Email:
Password:

Keppra

This page shows the latest Keppra news and features for those working in and with pharma, biotech and healthcare.

UCB bags FDA approval for epilepsy drug Briviact

UCB bags FDA approval for epilepsy drug Briviact

Belgium-headquartered UCB is already an established player in epilepsy with drugs such as Vimpat (lacosamide) and Keppra (levetiracetam), which is off-patent in most major markets. ... Briviact is positioned as a successor to Keppra, which despite

Latest news

More from news
Approximately 1 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Interview with Roch Doliveux, UCB Interview with Roch Doliveux, UCB

    Though Keppra is now off patent in the US and going off patent in the EU in 2011, it will still be a significant product for many years to come because ... Our largest patent expiries – the trigger to make big changes - were going to occur (and did

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics